The Week of May 6 in Review
The week of May 6 in review, featuring stories and videos on cabozantinib in medullary thyroid cancer, biomarkers in prostate cancer, and SAR302503 in myelofibrosis.
Dr. Landgren on the Standard of Care for Myeloma in 2013
Dr. Petrylak on Biomarker Discovery in Advanced Prostate Cancer
Mechanism of Action: Cetuximab
Penny Daugherty Comments on the Presence of a BRCA Mutation
Dr. Piccart on the Changing View of Anti-HER2 Therapies
TweetOla Landgren, MD, PhD, Head, Multiple Myeloma Section, National Cancer Institute, discusses the standard of care for myeloma in 2013.Daniel P. Petrylak, MD, director, Prostate and Genitourinary Cancer Program, co-director, Signal Transduction Research Program, at the Smilow Cancer Center at Yale-New Haven, discusses potential biomarkers currently being explored in castration-resistant prostate cancer (CRPC).Cetuximab is an epidermal growth factor receptor inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer.Penny Daugherty, RN, MS, OCN, Southeastern Gynecologic Oncology, comments on the presence of a BRCA mutation in her patients.Martine Piccart, MD, PhD, director of medicine at the Jules Bordet Institute in Brussels, Belgium, discusses the changing view of anti-HER2 therapies for patients with breast cancer.
Cabozantinib in Medullary Thyroid Cancer
Dr. Howard Scher on Findings From the COU-AA-302 Trial
PI3K Inhibitors in Breast Cancer Treatment
Dr. Zaks Describes the Mechanism of Action of SAR302503
Turning Concept Into Reality: Modulating the Immune System to Treat NSCLC
Dr. Leonard Gomella on Utilizing CTCs in Solid Tumors
Cabozantinib is a novel, small-molecule, multitargeted receptor tyrosine kinase inhibitor with particular activity against MET, VEGFR-2, and RET.Howard I. Scher, MD, Chief of the Genitourinary Oncology Service at the Sidney Kimmel Center for Prostate and Urologic Cancers at Memorial Sloan-Kettering Cancer Center, discusses an updated analysis of the COU-AA-302 trial.Aberrant activation of the PI3K pathway occurs frequently in breast cancer and contributes to treatment resistance to standard therapy.Tal Zaks, MD, PhD, vice president and head of development at Sanofi Oncology, explains the mechanism of action of SAR302503, a tyrosine kinase inhibitor being investigated in a phase III trial in patients with intermediate-2 or high-risk myelofibrosis.For many years nonsmall cell lung cancer (NSCLC), unlike melanoma and renal cell carcinoma, was thought to be a nonimmunogenic tumor unlikely to benefit from therapies aimed at augmenting endogenous antitumor immunity.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Ilson Examines Chemoimmunotherapy Regimens for Metastatic Gastroesophageal Cancers
December 20th 2024During a Case-Based Roundtable® event, David H. Ilson, MD, PhD, discussed the outcomes of the CheckMate 649, CheckMate 648, and KEYNOTE-859 trials of chemoimmunotherapy regimens in patients with upper GI cancers.
Read More
Navigating ESR1 Mutations in HR-Positive Breast Cancer With Dr Wander
October 31st 2024In this episode of Targeted Talks, Seth Wander, MD, PhD, discusses the clinical importance of ESR1 mutations in HR-positive metastatic breast cancer and how these mutations influence treatment approaches.
Listen
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
